Malaysian Herbs in Snake Bite: A Review
Keywords:
snake bites, medicinal plants, herbs, MalaysiaAbstract
Snake bite is a well-known life threatening menace that is commonplace in rural areas. Most of the rural people seem to prefer the use of medicinal plants/herbs to treat snake bites due to two major reasons; one that these herbs have been traditionally considered effective and the other that access to modern health services are limited. This review presents the current scenario on the use of such medicinal plants/herbs found in Malaysia with main focus on a few species that have been identified as traditionally chosen viz. Clinacanthus nutans (C. nutans), Acanthus ilicifolius (A. ilicifolius), Mimosa pudica (M. pudica), Andrographis paniculata (A. paniculata), Pogostemon cablin (P. cablin) and Murraya koenigii (M. koenigii). The leaves of C. nutans and P. cablin, leaves, fruit pulp, shoots and roots of A. ilicifolius, leaves and roots of M. pudica, leaves, roots and whole plant of A. paniculata and the leaves and bark of M. koenigii have been traditionally used in the treatment of snake bites
References
Guideline: Management of Snakebite. Ministry of Health Malaysia, Putrajaya, Malaysia. 2017.
Gupta YK, Peshin SS. Do herbal medicines have potential for managing snake bite envenomation? Toxicol int. 2012;19(2):89.
Mahadevan S. Antisnake Venom reactions-A perspective. Drug Alert. 2005;1:1-2.
Shashidharamurthy R, Kemparaju K. Region-specific neutralization of Indian cobra (Naja naja) venom by polyclonal antibody raised against the eastern regional venom: A comparative study of the venoms from three different geographical distributions. Int. Immunopharmacol. 2007;7(1):61-69.
Tsai IH, Tsai HY, Wang YM, Warrell DA. Venom phospholipases of Russell's vipers from Myanmar and eastern India-cloning, characterization and phylogeographic analysis. Biochim Biophys Acta Proteins Proteom. 2007;1774(8):1020-1028.
Félix-Silva J, Silva-Junior AA, Zucolotto SM, Fernandes-Pedrosa MD. Medicinal plants for the treatment of local tissue damage induced by snake venoms: an overview from traditional use to pharmacological evidence. Evid Based Complement Alternat Med. 2017;52.
Gutiérrez JM, Warrell DA, Williams DJ, Jensen S, Brown N et., Global Snakebite Initiative. The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: the way forward. PLoS Negl Trop Dis. 2013;7(6):e2162.
Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Lalloo DG. Snake envenoming: a disease of poverty. PLoS Negl Trop Dis. 2009;3(12):e569.
Sulochana AK, Raveendran D, Krishnamma AP, Oommen OV. Ethnomedicinal plants used for snake envenomation by folk traditional practitioners from Kallar forest region of South Western Ghats, Kerala, India. J Intercult Ethnopharmacol. 2015;4(1):47.
Martz W. Plants with a reputation against snakebite. Toxicon. 1992;30(10):1131-42.
Houghton PJ, Osibogun IM. Flowering plants used against snakebite. J Ethnopharmacol. 1993;39(1):1-29.
Aslam MS, Ahmad MS, Mamat AS. A review on phytochemical constituents and pharmacological activities of Clinacanthus nutans. Int J Pharm Pharm. 2015;7(2):30.
Alam A, Ferdosh S, Ghafoor K, Hakim A, Juraimi AS et al., Clinacanthus nutans: A review of the medicinal uses, pharmacology and phytochemistry. Asian Pac J Trop Dis. 2016;9(4):402-409.
Nantana S, Chayan P. Herbal Medicines Used in Primary Health Care in ASEAN. Department for Development of Thai Traditional and Alternative Medicine. 2014;123.
Sookmai W, Ekalaksananan T, Pientong C, Sakdarat S, Kongyingyoes B. The anti-papillomavirus infectivity of Clinacanthus nutans compounds. Srinagarind Med J. 2011;26:240-243.
Tuntiwachwuttikul P, Pootaeng-On Y, Phansa P, Taylor WC. Cerebrosides and a monoacylmonogalactosylglycerol from Clinacanthus nutans. Chem Pharm Bull. 2004;52(1):27-32.
Sakdarat S, Shuyprom A, Ayudhya TD, Waterman PG, Karagianis G. Chemical composition investigation of the Clinacanthus nutans Lindau leaves. Thai J Pharmacol. 2006;13(2):13-24.
Sakdarat S, Shuyprom A, Pientong C, Ekalaksananan T, Thongchai S. Bioactive constituents from the leaves of Clinacanthus nutans Lindau. Bioorg Med Chem. 2009;17(5):1857-1860.
Cherdchu C, Poopyruchpong N, Adchariyasucha R, Ratanabanangkoon K. The absence of antagonism between extracts of Clinacanthus nutans Burm. and Naja naja siamensis venom. Southeast Asian J Trop Med Public Health. 1977;8(2):249-254.
Xie LS, Liao YK, Huang QF, Huang MC. Pharmacognostic studies on mangrove Acanthus ilicifolius. Zhongguo Zhong Yao Za Zhi. 2005;30(19):1501-1503.
Ong HC. Acanthus ilicifolius L. In: van Valkenburg JLCH, Bunyapraphatsara N, editors. Plant Resources of South-East Asia No. 12(2): Medicinal and poisonous plants 2. Leiden, Netherlands: Backhuys Publishers, 2001;38.
Quattrocchi U. CRC world dictionary of medicinal and poisonous plants: Common names, scientific names, eponyms, synonyms, and etymology. Volume I A-B. Boca Raton, Florida: CRC Press, 2012;43.
Mastaller M. Mangroves: The Forgotten Forest between Land and Sea. Tropical Press; 1997;97.
Burkill IH. A dictionary of the economic products of the Malay Peninsula. Volume 1. London: Published on behalf of the governments of the Straits settlements and Federated Malay states by the Crown agents for the colonies. 1935;27-28.
Babu BH, Shylesh BS, Padikkala J. Antioxidant and hepatoprotective effect of Acanthus ilicifolius. Fitoterapia. 2001;72(3):272-277.
Kumaravel S, Vinoth R, Ranganathan R. Evaluation of Morpho-Anatomical Characters of Pichavaram Mangrove Plants. Int J Pharm Biol.Sci. 2018;8(4):544-552.
Patra JK, Dhal NK, Thatoi H. Free radical scavenging potential of four ethnomedicinally important mangrove plants along Odisha coast, India. Indian J Geo-Mar Sci. 2014;43(12):2189-2197.
Singh D, Aeri V. Phytochemical and pharmacological potential of Acanthus ilicifolius. J Pharm Bioallied Sci. 2013;5(1):17.
Joseph B, George J, Mohan J. Pharmacology and traditional uses of Mimosa pudica. Int J Pharm Sci Drug Res. 2013;5(2):41-44.
Muhammad G, Hussain MA, Jantan I, Bukhari SN. Mimosa pudica L., a highâ€value medicinal plant as a source of bioactives for pharmaceuticals. Compr Rev Food Sci Food Saf 2016;15(2):303-315.
Ahuchaogu AA, Chukwu OJ, Obike AI. Quantitative Determination of Secondary Metabolites and Antibacterial Activity of Mimosa Pudica. Int J Med Plants Nat Prod. 2017;3(2):1-5.
Ahmad H, Sehgal S, Mishra A, Gupta R. Mimosa pudica L. (Laajvanti): an overview. Pharmacogn Rev. 2012;6(12):115.
Pattanaik C, Reddy CS, Dhal NK. Phytomedicinal study of coastal sand dune species of Orissa. Indian J Tradit Knowl. 2008;7(2): 263-268.
Mahanta M, Mukherjee AK. Neutralisation of lethality, myotoxicity and toxic enzymes of Naja kaouthia venom by Mimosa pudica root extracts. J Ethnopharmacol. 2001;75(1):55-60.
Meenatchisundaram S, Michael A. Preliminary studies on antivenom activity of Mimosa pudica root extracts against Russell’s viper and saw scaled viper venom by in vivo and in vitro methods. Pharmacologyonline. 2009;2:372-374.
Bhalla NP, Sahu TR, Mishra GP, Dakwale RN. Traditional plant medicines of Sagar district, Madhya Pradesh, India. J Econ Taxon Bot. 1982;3:23-32.
Macmillan HF. Drugs, medicinal plants, masticatories and poisons. Tropical Planting and Gardening with Special Reference to Ceylon. Asian Educational Services. 1999:367.
Pattanaik C, Reddy CS, Dhal NK, Das R. Some phytotherapeutic claims by tribals of Rayagada district, Orissa, India. Ethnobot Leaflets. 2006;10;189–197.
Thirumalai T, Elumalai EK, Therasa SV, Senthilkumar B, David E. Ethnobotanical survey of folklore plants for the treatment of jaundice and snakebites in Vellore districts of Tamilnadu, India. Ethnobot Leaflets. 2010;14;529–536.
Kala CP. Herbal treatment for snakebites in Uttarakhand state of India. Indian J Nat Prod Resour. 2015;6(1):56–61.
Lenka D, Mohapatra A. Traditonal health care practices among Kondh and Bhuyan Tribes of Odisha. Int J Emerg Trends Sci Technol. 2015;2(1):1752–1757.
Vijayakumar S, Yabesh JEM, Prabhu S, Manikandan R, Muralidharan B. Quantitative ethnomedicinal study of plants used in the Nelliyampathy hills of Kerala, India. J Ethnopharmacol. 2015;161:238–254.
Upasani SV, Beldar VG, Tatiya AU, Upasani MS, Surana SJ et al., Ethnomedicinal plants used for snakebite in India: a brief overview. Integr Med Res. 2017;6(2):114-130.
Kligler B, Ulbricht C, Basch E, Kirkwood CD, Abrams TR et al., Andrographis paniculata for the treatment of upper respiratory infection: a systematic review by the natural standard research collaboration. Explore (New York, NY). 2006; 2(1):25-29.
Chao WW, Lin BF. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin Med. 2010;5(1):1-5.
Sule A, Ahmed QU, Samah OA, Omar MN. Screening for antibacterial activity of Andrographis paniculata used in Malaysian folkloric medicine: a possible alternative for the treatment of skin infections. Ethnobot Leaflets. 2010;2010(4):445-456.
Sanjutha S, Subramanian S, Rani CI, Maheswari J. Integrated nutrient management in Andrographis paniculata. Res J Agric & Biol Sci. 2008;4(2):141-145.
Samy RP, Thwin MM, Gopalakrishnakone P, Ignacimuthu S. Ethnobotanical survey of folk plants for the treatment of snakebites in Southern part of Tamilnadu, India. J Ethnopharmacol. 2008;115(2):302-312.
Rajadurai M, Vidhya VG, Ramya M, Bhaskar A. Ethno-medicinal plants used by the traditional healers of Pachamalai hills, Tamilnadu, India. Stud EthnoMed. 2009;3(1):39-41.
Gopi K, Renu K, Raj M, Kumar D, Muthuvelan B. The neutralization effect of methanol extract of Andrographis paniculata on Indian cobra Naja naja snake venom. J Pharm Res. 2011;4(4):1010-1012.
Sivakumar A, Manikandan A, Rajini Raja M, Jayaraman G. Andrographis paniculata leaf extracts as potential Naja naja anti-snake venom. World J Pharm Sci. 2015; 4:1036-1050.
Kumar RSAS, Joshua AV, Sangeetha M, Thilagavathy D, Gnanaiah S. Isolation, purification and characterization of active compound from Andrographis paniculata L. and testing its anti-venom and cytotoxic activity by in-vitro and in-vivo studies. Int J Res Ayurveda Pharm. 2014;5(2):163-168.
Swamy MK, Sinniah UR. A comprehensive review on the phytochemical constituents and pharmacological activities of Pogostemon cablin Benth.: an aromatic medicinal plant of industrial importance. Molecules. 2015;20(5):8521-8547.
Swamy MK, Balasubramanya S, Anuradha M. In vitro multiplication of Pogostemon cablin Benth. through direct regeneration. Afr J Biotechnol. 2010;9(14):2069-2075.
China Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; Chemical Industry Press: Beijing, China, 2010;Volume 1:42–46.
Das K. Patchouli (Pogostemon cablin Benth) oils. In Essential Oils in Food Preservation, Flavor and Safety.
Academic Press. 2016;633-639.
Prakash V, Natarajan CP. Studies on curry leaf (Murraya koenigii L). J Food Sci Technol. 1974;11(6):284-286.
Kesari AN, Kesari S, Singh SK, Gupta RK, Watal G. Studies on the glycemic and lipidemic effect of Murraya koenigii in experimental animals. J Ethnopharmacol. 2007;112(2):305-311.
Nagappan T, Ramasamy P, Vairappan CS. Chemotaxonomical markers in essential oil of Murraya koenigii. Nat Prod Commun. 2012;7(10):1375-1378.
Yun-Cheung K, Kam-Hung N, Pui-Hay BP, Qian L, Si-Xao Y, Hong-Ta Z et al., Sources of the anti-implantation alkaloid yuehchukene in the genus Murraya. J Ethnopharmacol. 1986;15(2):195-200.
Verma S. A study on a highly medicinal plant Murraya koenigii: Rutaceae. Pharma Innov J. 2018;7(7):283-285.
Handral HK, Pandith A, Shruthi SD. A review on Murraya koenigii: multipotential medicinal plant. Asian J Pharm Clin Res. 2012;5(4):5-14.
Downloads
Additional Files
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
